Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7296066 | 0.85 | SIRT2 (0.75) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL27207676 | 0.84 | TP53 (0.64) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL8900040 | 0.84 | LMNA (0.66) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL14788168 | 0.84 | SIRT2 (0.74) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL17513948 | 0.84 | SIRT2 (0.65) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL7952282 | 0.83 | SIRT2 (0.72) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 | |
| SCHEMBL1544017 | 0.82 | MAPT (0.65) | SMN1; SMN2MAPK1NPC1RAB9AMAPT | |
| SCHEMBL10904042 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRMAPK1L3MBTL1NPC1 | |
| SCHEMBL2538786 | 0.81 | LMNA (0.67) | SMN1; SMN2TSHRMAPK1L3MBTL1NPC1 | |
| SCHEMBL7148635 | 0.81 | SIRT2 (0.70) | SMN1; SMN2TSHRALOX15MAPK1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093377-B | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115093377-A | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2022-09-23 | — | — | CN | claimed |
| EP-0504574-B1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | WAKAMOTO PHARMA CO LTD (JP) | 1996-02-28 | — | — | EP | claimed |
| CN-115093377-B | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115093377-A | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2022-09-23 | — | — | CN | disclosed |
| EP-1937673-B1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-8044208-B2 | inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178877-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GlaxoSmithKline LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | LEIVERS MARTIN ROBERT | 2010-02-04 | — | — | US | disclosed |
| WO-2007045339-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (DE) | 2007-04-26 | — | — | WO | disclosed |
| EP-0767782-B1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6166020-A | Aryl and heteroaryl alkoxynaphthalene derivatives | PFIZER INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0767782-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0504574-B1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | WAKAMOTO PHARMA CO LTD (JP) | 1996-02-28 | — | — | EP | disclosed |
| WO-1996000720-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| US-4497804-A | Insecticidal, acaricidal, and nematicidal O-ethyl S-alkyl S-(1,2,4-oxadiazol-5-yl-methyl) phosphorodithiolate derivatives, compositions, and methods of use | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, RPL35 | SMN1; SMN2 495/4885TSHR 4864/4885ALOX15 1763/4885 |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | RPL35, HAVCR2, RPL5 | SMN1; SMN2 2027/4885TSHR 4860/4885ALOX15 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.